key: cord-0707118-xsgp9j13
authors: Pakhchanian, Haig; Raiker, Rahul; DeYoung, Charles; Yang, Sherry
title: Evaluating the safety and efficacy of COVID‐19 vaccination in patients with hidradenitis suppurativa
date: 2022-02-18
journal: Clin Exp Dermatol
DOI: 10.1111/ced.15090
sha: 95dfe6cca9e9736a837c40f4fb1bb5c7eec2b7fd
doc_id: 707118
cord_uid: xsgp9j13

nan

1 propensity score matching analysis to balance each cohort by demographics (age, sex and race) and comorbidities (diabetes mellitus, essential HTN, CLRD, chronic kidney disease, nicotine dependence, alcohol dependence, heart failure, ischaemic heart disease, BMI and neoplasms. b The algorithm used for propensity score matching excluded two patients from the HS group, as these two patients were difficult to match given their unique combination of demographics and comorbidities.

Clinical and Experimental Dermatology examined using hazard ratios that was estimated using the proportional hazard model to measure efficacy. A subgroup analysis was conducted on patients with HS with a 1-year history of systemic antibiotics or tumour necrosis factor (TNF) inhibitors. Further information regarding the methodology is detailed elsewhere. 5 In total, 1 279 188 vaccinated patients were identified, of whom 3418 had prior HS. Compared with the control cohort, the HS cohort was younger and had higher numbers of black patients, female patients and patients with coexisting comorbidities ( Table 1 ). The percentage of patients with HS receiving any dose of the BNT162b2, mRNA-1273 and Ad26.COV.2.S vaccines was 83%, 14.5% and 2.5%, respectively. After matching, the risk for any outcome between HS and non-HS vaccinated patients was not significantly different ( Table 2) . Similarly, there was no significant difference in any assessed outcome among matched patients with HS with or without a 1-year history of systemic antibiotics or TNF inhibitors.

This is the first large-scale study to investigate the safety and efficacy of COVID-19 vaccines among patients with HS, and the results show that patients with HS are not at any higher risk for any vaccine-related adverse outcomes. Furthermore, patients with HS on systemic medications within 1 year of being vaccinated have similar outcomes to those not receiving medications, demonstrating that anti-inflammatory/immunosuppressive therapy should not be viewed as a contraindication to vaccination. Although the prevalence of adverse events is rare, it can be concluded that COVID-19 vaccines are most likely safe and effective among patients with HS, even among those on systemic medications. As HS comorbidities are shown to be associated with worse COVID-19 outcomes, 5 avoiding vaccination may pose greater risks in patients with HS and comorbidities.

The limitations of this study are intrinsic to databases based on electronic medical records. The impact of HS severity or vaccine-induced nonspecific symptoms could not be examined and possible errors in coding entry may have existed. Further studies examining the influence of HS severity on outcomes and longer follow-up times are warranted. 

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine

Coronavirus disease 2019 complications in patients with hidradenitis suppurativa: a multicenter analysis

COVID-19 vaccination is safe and effective in patients with inflammatory bowel disease: analysis of a large multiinstitutional research network in the United States

Additional Supporting Information may be found in the online version of this article: Data S1 Additional information.